46 Participants Needed

Quad Therapy for Multiple Myeloma

EE
CC
Overseen ByCaitlin Costello, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of California, San Diego
Must be taking: Aspirin, Warfarin, Heparin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot use certain strong medications like rifampin or St. John's wort within 14 days before starting the trial. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug combination used in the Quad Therapy for Multiple Myeloma?

Research shows that combining daratumumab with pomalidomide and dexamethasone improved progression-free survival in patients with previously treated multiple myeloma. Additionally, a study found that ixazomib with pomalidomide and dexamethasone had a 51.7% overall response rate in patients with resistant multiple myeloma, suggesting the potential effectiveness of these drugs in combination.12345

Is Quad Therapy for Multiple Myeloma safe for humans?

The combination of drugs used in Quad Therapy, including Ixazomib, Daratumumab, Pomalidomide, and Dexamethasone, has been studied in various trials for multiple myeloma. These studies show that while the treatment is generally well-tolerated, some patients may experience side effects like fatigue, infections, and blood-related issues (such as low blood cell counts).24678

What makes the Quad Therapy for Multiple Myeloma unique?

The Quad Therapy for Multiple Myeloma is unique because it combines four drugs—Daratumumab, Dexamethasone, Ixazomib, and Pomalidomide—each with different mechanisms to target the cancer cells, potentially improving treatment effectiveness compared to using fewer drugs. This combination aims to enhance progression-free survival and is particularly beneficial for patients who have already undergone other treatments.134910

What is the purpose of this trial?

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

Research Team

CC

Caitlin Costello, MD

Principal Investigator

University of California, San Diego

Eligibility Criteria

This trial is for adults with Multiple Myeloma who've had 1-3 prior treatments but haven't used Daratumumab or Ixazomib before. They must not be pregnant, agree to birth control measures, and join the POMALYST REMS program. Participants should have a life expectancy over 3 months, an ECOG status of 0-2, and adequate organ function.

Inclusion Criteria

My liver is working well.
I agree to use two forms of birth control or abstain from sex for 120 days after the last dose.
I agree to take daily aspirin or, if I have a history of blood clots, to be on full anticoagulation treatment.
See 15 more

Exclusion Criteria

My condition did not improve after taking pomalidomide.
I have previously used daratumumab or ixazomib.
I am HIV positive or suspected to be.
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as salvage therapy

16 weeks
Weekly visits for 8 weeks, biweekly for 8 weeks, then monthly

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years

Long-term follow-up

Participants are monitored for progression-free survival and overall survival

Up to 100 months

Treatment Details

Interventions

  • Daratumumab
  • Dexamethasone
  • Ixazomib
  • Pomalidomide
Trial Overview The study tests a combination therapy using Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in patients with relapsed/refractory Multiple Myeloma. It aims to evaluate the overall response rate to this salvage therapy regimen.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: ixazomib, daratumumab, pomalidomide and dexamethasoneExperimental Treatment4 Interventions
Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.

Daratumumab is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Darzalex for:
  • Relapsed and refractory multiple myeloma
  • Newly diagnosed multiple myeloma in combination with bortezomib, melphalan, and prednisone
🇺🇸
Approved in United States as Darzalex for:
  • Multiple myeloma in patients who have received at least three prior therapies
  • Newly diagnosed multiple myeloma in combination with bortezomib, melphalan, and prednisone
  • Relapsed or refractory multiple myeloma in combination with lenalidomide and dexamethasone

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, San Diego

Lead Sponsor

Trials
1,215
Recruited
1,593,000+

Celgene

Industry Sponsor

Trials
649
Recruited
130,000+
Top Products
>- **Revlimid (lenalidomide)**: Multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma treatment. - **Pomalyst (pomalidomide)**: Relapsed/refractory multiple myeloma treatment. - **Otezla (apremilast)**: Psoriatic arthritis treatment. - **Thalomid (thalidomide)**: Erythema nodosum leprosum and multiple myeloma treatment.
Jay Backstrom profile image

Jay Backstrom

Celgene

Chief Medical Officer since 2016

MD

Mark Alles profile image

Mark Alles

Celgene

Chief Executive Officer since 2016

Bachelor's degree from Lock Haven University of Pennsylvania

Takeda

Industry Sponsor

Trials
1,255
Recruited
4,219,000+
Dr. Naoyoshi Hirota profile image

Dr. Naoyoshi Hirota

Takeda

Chief Medical Officer since 2020

MD from University of Tokyo

Christophe Weber profile image

Christophe Weber

Takeda

Chief Executive Officer since 2015

PhD in Molecular Biology from Université de Montpellier

Janssen, LP

Industry Sponsor

Trials
169
Recruited
329,000+
Founded
1953
Headquarters
Beerse, Belgium
Known For
Mental Health Therapies
Top Products
Imodium, Remicade, Invega, Procrit
Joaquin Duato profile image

Joaquin Duato

Janssen, LP

Chief Executive Officer since 2022

MBA from ESADE Business School

Biljana Naumovic profile image

Biljana Naumovic

Janssen, LP

Chief Medical Officer since 2023

MD from Belgrade University Medical School

Findings from Research

Daratumumab significantly improves overall survival (OS) compared to pomalidomide plus low-dose dexamethasone in patients with heavily pretreated multiple myeloma, with hazard ratios indicating a strong treatment benefit (0.56 and 0.51 for two different studies).
The survival advantage of daratumumab is even more pronounced in patients who have not previously been treated with pomalidomide, suggesting it may be particularly effective in this subgroup.
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.Van Sanden, S., Ito, T., Diels, J., et al.[2019]
In a phase II study involving 65 intermediate-fit patients with newly diagnosed multiple myeloma, the combination of Ixazomib, Daratumumab, and low-dose dexamethasone resulted in a 71% overall response rate during induction therapy, indicating its efficacy as a first-line treatment.
While the treatment improved global quality of life significantly, it also led to frequent dose modifications due to low-grade polyneuropathy, suggesting that the regimen's long-term tolerability may be a concern for patients.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.Groen, K., Stege, CAM., Nasserinejad, K., et al.[2023]
In a phase 3 trial involving 304 patients with relapsed or refractory multiple myeloma, the combination of daratumumab with pomalidomide and dexamethasone significantly improved progression-free survival compared to pomalidomide and dexamethasone alone, with a median of 12.4 months versus 6.9 months.
While the combination treatment was effective, it was associated with a higher incidence of grade 3 or 4 adverse events, particularly neutropenia, indicating that while daratumumab enhances treatment efficacy, it may also increase the risk of serious side effects.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.Dimopoulos, MA., Terpos, E., Boccadoro, M., et al.[2021]

References

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison. [2019]
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial. [2023]
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. [2021]
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. [2021]
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). [2022]
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. [2020]
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. [2018]
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program. [2020]
Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study. [2023]
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security